Safety and efficacy evaluation of albumin-bound paclitaxel.

abstract：INTRODUCTION:Since calcitonin gene-related peptide (CGRP) plays an important role in the pathophysiology of migraine via the activation of the trigeminovascular system, the newest prophylactic treatments directly block CGRP or its receptor. However, the safety of these novel antimigraine drugs is not yet sufficiently e...

journal_title：Expert opinion on drug safety

authors： Rivera-Mancilla E,Villalón CM,MaassenVanDenBrink A

更新日期：2020-10-01 00:00:00

abstract：:Many diseases are now treatable with modern drugs. Elderly people, because they suffer from age-related illnesses, stand to gain the most, but they are also at risk from adverse drug reactions (ADRs). There are complex reasons for the increased frequency of ADRs, including poor prescribing, polypharmacy, altered drug ...

journal_title：Expert opinion on drug safety

authors： Beard K

更新日期：2003-05-01 00:00:00

abstract：INTRODUCTION:The Annual Meeting of the Safety Pharmacology (SP) Society is a yearly event designed to keep attendees abreast of how to best identify and mitigate organ function liabilities of candidate drugs selected for clinical assessment. AREAS COVERED:Heart rate (HR) and blood pressure (BP) effects of candidate dr...

journal_title：Expert opinion on drug safety

authors： Cavero I

更新日期：2015-06-01 00:00:00

abstract：:Given the fact that as many as 9% of all adverse drug reactions involve toxic effects on the liver and with upwards of 50% of all cases of fulminant hepatic failure being ascribed to acetaminophen and other agents, the safe use of medications takes on an even greater importance whenever the prescription of potentially...

journal_title：Expert opinion on drug safety

authors： Lewis JH

更新日期：2002-07-01 00:00:00

abstract：OBJECTIVE:The aim of this study was to investigate whether the use of statins was associated with a decreased risk of gallstone disease. METHODS:We conducted a population-based case-control study in Taiwan. Cases consisted of all patients who were aged 50 years and older and had a first-time diagnosis of gallstone dis...

journal_title：Expert opinion on drug safety

authors： Chiu HF,Chen CC,Kuo HW,Lee IM,Wu TN,Yang CY

更新日期：2012-05-01 00:00:00

abstract：:Of the numerous topics discussed during the eighth annual meeting of the Safety Pharmacology (SP) Society the author identified the following key topics: i) the impact of hERG (human ether-à-go-go related gene) channel data on drug development, ii) safety evaluation of biological products, iii) opportunities and expec...

journal_title：Expert opinion on drug safety

authors： Cavero I,Safety Pharmacology Society.

更新日期：2009-03-01 00:00:00

abstract：:Recombinant activated Factor VII (rFVIIa) has been successfully used in the treatment of haemophilia A and B with associated inhibitors for some years. Activated Factor VII binds to activated platelets independently of tissue factor. The resulting stimulation of an exaggerated early thrombin burst at sites of vascular...

journal_title：Expert opinion on drug safety

authors： Wilson SJ,Bellamy MC,Giannoudis PV

更新日期：2005-05-01 00:00:00

abstract：INTRODUCTION:The approval of sofosbuvir (SOF), a nucleotide analogue NS5B polymerase inhibitor, and ledipasvir (LDV), a NS5A inhibitor, marked a new chapter in IFN and ribavirin-free treatment of hepatitis C virus (HCV). This drug reduces adverse events associated with IFN therapy. AREAS COVERED:The purpose of this pa...

journal_title：Expert opinion on drug safety

authors： Fazel Y,Lam B,Golabi P,Younossi Z

更新日期：2015-08-01 00:00:00

abstract：INTRODUCTION:The polycystic ovary syndrome (PCOS) is a very prevalent disorder in premenopausal women. Cardiovascular risk factors cluster in these patients, raising concern about the safety of the drugs commonly used to ameliorate symptoms of androgen excess in in this population at risk of cardiovascular morbidity. ...

journal_title：Expert opinion on drug safety

authors： Luque-Ramírez M,Ortiz-Flores AE,Nattero-Chávez L,Escobar-Morreale HF

更新日期：2020-12-01 00:00:00

abstract：INTRODUCTION:ACE inhibitors are first-line therapy in patients with chronic kidney disease (CKD). The main adverse effects of ACE inhibitors are hypotension, renal function impairment and hyperkalemia. AREAS COVERED:This paper reviews evidence from clinical studies regarding adverse effects of ACE inhibitors in patien...

journal_title：Expert opinion on drug safety

authors： Sidorenkov G,Navis G

更新日期：2014-10-01 00:00:00

abstract：INTRODUCTION:Alemtuzumab is a humanised anti-CD52 mAb which has recently been licensed for the treatment of relapsing multiple sclerosis in Europe. AREAS COVERED:The efficacy and safety of alemtuzumab from open label, Phase II and Phase III trials is reported. EXPERT OPINION:Alemtuzumab causes rapid and profound comp...

journal_title：Expert opinion on drug safety

authors： Willis M,Robertson NP

更新日期：2014-08-01 00:00:00

abstract：:Bone morphogenetic proteins (BMPs) have been extensively studied since the discovery of agents within bone that could induce bone formation at ectopic sites by Urist in the 1960s. Extensive preclinical research has been carried out showing the efficacy of these products in promoting bone healing. Clinical trials are e...

journal_title：Expert opinion on drug safety

authors： Harwood PJ,Giannoudis PV

更新日期：2005-01-01 00:00:00

abstract：INTRODUCTION:Oral antidiabetic medications are important in many type 2 diabetes care plans. AREAS COVERED:The article summarizes the cardiovascular and renal safety data for DPP-4 inhibitors and SGLT-2 inhibitors and specific safety data particular to each class. EXPERT OPINION:DPP-4 and SGLT-2 inhibitors provide un...

journal_title：Expert opinion on drug safety

authors： Lamos EM,Hedrington M,Davis SN

更新日期：2019-08-01 00:00:00

abstract：INTRODUCTION:Sulfasalazine (SASP) is a drug commonly used in the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease (CD) and rheumatoid arthritis (RA). A high incidence of side effects limits therapy with this drug. Getting a wider knowledge of drug pharmacology, indications a...

journal_title：Expert opinion on drug safety

authors： Linares V,Alonso V,Domingo JL

更新日期：2011-03-01 00:00:00

abstract：INTRODUCTION:The goal of antiviral therapy in patients with chronic hepatitis C is to slow or halt the progression of fibrosis and prevent the development of cirrhosis. Accordingly, antiviral treatment is proposed for a large population of patients with chronic hepatitis. AREAS COVERED:The standard-of-care for chronic...

journal_title：Expert opinion on drug safety

authors： Calvaruso V,Mazza M,Almasio PL

更新日期：2011-05-01 00:00:00

abstract：INTRODUCTION:Patients with end-stage renal disease (ESRD) are considered at higher risk of influenza-related complications and are listed worldwide among the subjects for whom yearly influenza vaccination is strongly recommended. However, influenza vaccination coverage of patients with ESRD is significantly lower than ...

journal_title：Expert opinion on drug safety

authors： Principi N,Esposito S,ESCMID Vaccine Study Group (EVASG).

更新日期：2015-08-01 00:00:00

abstract：:Stroke is a common cause for morbidity and mortality, causing substantial economic costs. Because thrombosis plays a key role in the pathogenesis of ischaemic stroke, heparins, platelet inhibitors and anticoagulants have been used in stroke management. There were high hopes that patients might benefit from the use of ...

journal_title：Expert opinion on drug safety

authors： Kiphuth IC,Köhrmann M,Huttner HB,Schellinger PD

更新日期：2009-09-01 00:00:00

abstract：BACKGROUND:The nasal cavity is a vulnerable zone which may be damaged by vascular disorders. We systematically assessed the frequency and severity of nasal cavity alterations during bevacizumab treatment, to determine its clinical relevance and factors contributing to its onset. PATIENTS AND METHODS:We conducted a hos...

journal_title：Expert opinion on drug safety

authors： D'Amico M,Pagano M,Pasa A,Puntoni M,Clavarezza M,Gennari A,Gozza A,Zanardi S,Defferrari C,Provinciali N,Campazzi E,Campora S,Paleari L,Marra D,Petrera M,DeCensi A

更新日期：2014-11-01 00:00:00

abstract：INTRODUCTION:Approximately 40-50% of patients with cutaneous melanoma harbor point mutations in BRAF. BRAF and MEK inhibitors in combination are now a standard therapy for advanced BRAFV600-mutated melanoma. Nevertheless, survival rates with the combination are limited, highlighting the need for further therapeutic imp...

journal_title：Expert opinion on drug safety

authors： Indini A,Mandalà M

更新日期：2020-10-01 00:00:00

abstract：:The widespread application of protocols using gonadotropin-releasing hormone (GnRH) agonists or antagonists in assisted reproduction treatment has led to an increasing number of pregnancies exposed to these drugs. This issue has raised scepticism as to the safety of these medications, concerning both pregnant women an...

journal_title：Expert opinion on drug safety

authors： Tarlatzis BC,Bili H

更新日期：2004-01-01 00:00:00

abstract：INTRODUCTION:Many commonly used drugs have primary or secondary anticholinergic effects contributing to adverse outcomes ranging from mild-to-severe to potentially lethal. Anticholinergic adverse effects frequently occur with medications prescribed with other intended mechanisms of action, including antihistamines, ant...

journal_title：Expert opinion on drug safety

authors： Gerretsen P,Pollock BG

更新日期：2011-09-01 00:00:00

abstract：INTRODUCTION:Carbonic anhydrase (CA) inhibitors have an impressive safety record despite the multiple functions that CA isozymes serve because they are not fully inhibited with most dosing. While reducing the targeted CA-dependent process sufficiently for disease control, residual activity and uncatalyzed rates in comb...

journal_title：Expert opinion on drug safety

authors： Swenson ER

更新日期：2014-04-01 00:00:00

abstract：:Background: Erenumab has recently been approved as a pharmacological treatment for the prevention of migraine. However, the incidence estimates of adverse drug reactions (ADRs) were not consistent among studies. Consequently, pooled measures of the incidences of ADRs that accounts for inter-study heterogeneity are des...

journal_title：Expert opinion on drug safety

authors： Pellesi L,De Icco R,Alawie HY,Andersen M,Liang D,Amirguliyev S,Al-Karagholi MA,Amin FM,Sessa M

更新日期：2020-12-29 00:00:00

abstract：BACKGROUND:Clinical data on the long-term safety and efficacy of infliximab on psoriatic patients who are older than 65 years are limited. OBJECTIVES:The aim is to report the long-term efficacy, safety and tolerance of infliximab in geriatric patients. METHODS:This was a retrospective study conducted at the Departmen...

journal_title：Expert opinion on drug safety

authors： Chiricozzi A,Pavlidis A,Dattola A,Bianchi L,Chimenti MS,Fida M,Saraceno R

更新日期：2016-11-01 00:00:00

abstract：:Treating bipolar disorder in women during reproduction presents a significant challenge to the physician. The pharmaceutical agents most commonly used for treating bipolar disorder have been associated with adverse effects when used during pregnancy and breastfeeding. Of particular concern has been the association of ...

journal_title：Expert opinion on drug safety

authors： Dodd S,Berk M

更新日期：2004-05-01 00:00:00

abstract：INTRODUCTION:Over the past decade, increased prescription supply has facilitated an epidemic of nonmedical use of controlled substances, including predominantly opioids, as well as benzodiazepines, z-hypnotics, and stimulants. Areas covered: More recently, misuse of noncontrolled prescriptions, such as gabapentin, has ...

journal_title：Expert opinion on drug safety

authors： Peckham AM,Fairman KA,Sclar DA

更新日期：2018-05-01 00:00:00

abstract：INTRODUCTION:Lanreotide autogel is a synthetic somatostatin analogue which has been FDA and EMA approved for unresectable, well to moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumor. Its action is mediated by its affinity to somatostatin receptors, especially sst2 and ...

journal_title：Expert opinion on drug safety

authors： Godara A,Siddiqui NS,Byrne MM,Saif MW

更新日期：2019-01-01 00:00:00

abstract：:The use of warfarin in the elderly, particularly for stroke prevention in chronic atrial fibrillation, is steadily increasing. Although the benefits of warfarin are greatest in the elderly, so are the risk of adverse outcomes and the difficulties of anticoagulant management. Clinical systems need to improve to counter...

journal_title：Expert opinion on drug safety

authors： Bereznicki LR,Peterson GM,Jackson SL,Jeffrey EC

更新日期：2006-05-01 00:00:00

abstract：INTRODUCTION:Despite the significant advances in the pharmacological and interventional management of patients with cardiovascular disease (CVD) over the last decades, cardiovascular mortality remains the leading cause of death. Large randomized clinical trials have investigated the efficacy and safety of different ant...

journal_title：Expert opinion on drug safety

authors： Romano S,Buccheri S,Mehran R,Angiolillo DJ,Capodanno D

更新日期：2018-10-01 00:00:00

abstract：INTRODUCTION:In the past two decades, the number of women with autoimmune and inflammatory diseases experiencing a pregnancy has significantly increased in parallel with the enormous advances in the diagnosis and management of these disorders. However, information regarding the safety of immunosuppressive agents comes ...

journal_title：Expert opinion on drug safety

authors： Gerosa M,Meroni PL,Cimaz R

更新日期：2014-12-01 00:00:00